Fighting Parkinson’s Early: Can Immunotherapy Help Stop It in Its Tracks?

A group of researchers has put forward a new idea for tackling Parkinson’s in its earliest stages — long before major symptoms take hold. Instead of waiting until brain cells are already badly damaged, they believe immunotherapy (treatments that work by guiding or boosting the immune system) could be used earlier, with the help of biomarkers to spot people most likely to benefit. This approach is called secondary prevention — stepping in once early disease changes have started but before real disability appears. The focus is on people showing early signs of Parkinson’s or changes in certain biomarkers, such as abnormal levels of the protein alpha-synuclein, which builds up in the brains of people with the condition. The paper reviews current and past trials that tested antibody treatments designed to target and clear alpha-synuclein from the brain. These studies have shown that such drugs are generally safe, although some people experienced mild reactions during infusions. The challenge is that, so far, no trial has proved that immunotherapy actually slows or stops Parkinson’s progression in people. The researchers suggest a smarter way forward. Future trials should start earlier, choose participants based on biomarker profiles rather than just symptoms, and use more precise ways to measure whether a treatment is working inside the brain. They also argue that success should be judged not only by whether symptoms improve but by whether the underlying biology of Parkinson’s changes — something that biomarkers can reveal. Why does this matter? Because by the time most people are diagnosed with Parkinson’s, a large number of brain cells that control movement are already gone. By finding people earlier — perhaps even before tremors or stiffness appear — scientists hope to test therapies that protect neurons before it’s too late. For people living with Parkinson’s, this research doesn’t mean there’s a new treatment ready to use. But it does show the direction things are heading: earlier detection, more personalised treatments, and a shift from managing symptoms to trying to slow the disease itself.